GlassScriptPhysician profile
Nicholas Cane Becketti
NPI 1922488824
$1,829.75
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $201 · 2022: $23.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $349.71 | 2019-2020 | |
| Novo Nordisk INC | $190.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $186.08 | 2019 | |
| Amarin Pharma, INC. | $165.23 | 2019-2020 | |
| Allergan, INC. | $162.43 | 2019-2020 | |
| Glaxosmithkline, LLC. | $80.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.10 | 2019 | |
| Amgen INC. | $70.92 | 2019 | |
| Mannkind Corporation | $56.05 | 2019 | |
| Lilly USA, LLC | $53.87 | 2019 | |
| Senseonics, Incorporated | $50.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $43.50 | 2019 | |
| Vifor Pharma, INC. | $39.08 | 2019 | |
| Sanofi Pasteur INC. | $29.47 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.81 | 2019-2020 | |
| Shire North American Group INC | $24.83 | 2019 | |
| Abbvie INC. | $23.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.44 | 2019 | |
| Advanced Respiratory, INC | $20.35 | 2019 | |
| Mylan Specialty L.P. | $16.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.07 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.48 | 2019 | |
| Therapeuticsmd, INC. | $14.75 | 2019 | |
| Companion Medical, INC. | $13.55 | 2020 | |
| Vertiflex, INC. | $11.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Becketti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.